Ten Toxin Brands, One Ingredient Line: What a Spec Sheet Cannot Tell Apart

Put ten Korean toxin brands side by side and read only the ingredient line on each product page. All ten say the same thing: Clostridium botulinum toxin type A, 100 units. Not similar wording, the same wording, down to the phrasing that follows it. Two of the ten add a short qualifier and the other eight do not. The Korean drug register agrees with the product pages: across 58 licences, 54 carry an ingredient name identical to each other. This is a category where the specification line does not tell products apart, and knowing that changes what you ask a supplier.

Ten brands, and an ingredient line that does not move

Our toxin collection holds 18 active SKUs across ten brand names: NABOTA, INNOTOX, BOTULAX, WONDERTOX, CORETOX, METOX, FINETOX, LIZTOX, Kamomis and TOXTA. Several appear in more than one unit size, which accounts for the gap between ten brands and 18 SKUs.

Reading the declared active across all ten produces an unusually flat result. Every one declares Clostridium botulinum toxin type A. Every 100 unit presentation declares 100 units. The descriptive clause that follows is, in eight of the ten cases, word for word identical. If you built a comparison table from the ingredient line alone, you would produce ten rows that differ only in the brand column.

Two entries carry something extra, and both additions are about form or composition rather than about the active itself. INNOTOX describes a ready to use liquid presentation, which is a statement about what is in the vial physically rather than what molecule is in it. CORETOX describes a complex protein free preparation, which is a statement about what has been left out. Neither changes the declared active, and neither appears in the other eight.

This is worth stating plainly because it runs against how buyers are trained to compare products in every other category we sell. In fillers the ingredient line separates hyaluronic acid from poly-L-lactic acid. In boosters it separates PDRN from polynucleotide from glutathione, sometimes within a single brand family, as a reading of one five product brand showed in one brand name, five products that share almost nothing. Toxins invert that entirely: one ingredient line, many brands.

The register does the same thing, with four exceptions that matter

A reasonable next move is to check whether the official record is more discriminating than the storefront. It is not, and the way it fails to be is instructive.

Querying the Korean drug register for this active returns 58 licences, of which 57 remain valid, held by 21 companies and classified without exception under [06320], the toxins and toxoids class. Every one is prescription only. The size and shape of that entry, and what a settled category looks like next to a new one, is the subject of fifty-eight and zero, so this piece stays with a narrower question: what do the product names in those 58 records actually say.

One number in that entry is worth pausing on before the names, because it is unusual. Of 58 licences, exactly one is no longer valid, a withdrawal rate of 1.7 percent. Set against a sample of eleven other register queries where the rate ran from zero to 36.2 percent, that puts toxins among the most stable entries we have measured, and well below the 7.8 percent of the next lowest active category. What a withdrawal rate does and does not indicate, which is less than most people assume, is set out in the licences that left. Here it simply means the field of 58 has barely changed shape.

Almost all of them say the same thing. Scanning the licensed product names, 54 of 58 carry the ingredient rendered as 클로스트리디움보툴리눔독소A형, Clostridium botulinum toxin type A, with nothing further. Four do not, and every one of those four encodes a composition detail directly in the licensed name.

The first is Dysport, filed as 디스포트주(클로스트리디움보툴리눔A형독소-혈구응집소복합체). That trailing term, 혈구응집소복합체, means haemagglutinin complex, and it is exactly the complex protein that CORETOX advertises the absence of. The other three put a molecular weight inside the licensed name instead. Two of them are Xeomin filings, 제오민주(클로스트리디움 보툴리눔 독소 A형(150kDa)) granted in 2009 and 제오민주50단위 in 2018. The third is CORETOX itself, filed as 코어톡스주(클로스트리디움보툴리눔독소A형(150kDa)), which means the claim its ingredient line makes on our product page is also written into its official name. Four filings out of 58 put a compositional fact into the licensed name; the other 54 leave it out.

Other categories put composition in the licensed name, this one does not

The flatness only becomes visible as a property of this category when you look at how other registers entries are named. Korean licensed product names are not generally silent about composition; several categories put a surprising amount of detail directly into the name.

Hyaluronic acid provides the clearest contrast. One licensed injectable is filed as 휴미아주(1,4-부탄디올디글리시딜에테르로 가교된 히알루론산나트륨 겔), which names not only the substance but the specific cross-linking agent used to make it. That is a manufacturing detail carried in an official product name. Placenta preparations split at the ingredient level into 자하거추출물 and 자하거가수분해물, extract and hydrolysate, keeping a processing distinction visible across every licence in the entry. PDRN is filed under its full chemical rendering rather than an abbreviation.

Against those, 54 toxin licences reading 클로스트리디움보툴리눔독소A형 and nothing more is a genuinely different convention. It is not that Korean naming lacks the capacity to record composition. It is that this particular category has settled on a name that records the active and stops, and the four exceptions show the capacity was available all along.

Why that happened is not something a register answers, and speculating would be inventing a cause for a real observation. What follows practically is only this: a technique that works in other categories, reading the licensed name for compositional signal, returns almost nothing here. A buyer who has learned to check the licensed name for filler cross-linking or placenta processing will find the same check produces no discrimination among toxins, and should not read that emptiness as sameness.

What "complex protein free" is a claim about

CORETOX is the one product in our range whose ingredient line makes a compositional claim, and it is a negative one. Understanding what kind of statement that is, without evaluating whether it matters clinically, is useful for reading the rest of the category.

Botulinum toxin as produced by the bacterium does not arrive as a bare molecule. It associates with accessory proteins, and the haemagglutinin complex named in the Dysport licence is one such association. Preparations differ in whether those accessory proteins are carried through into the finished product or removed during purification. A complex protein free preparation is stating that they have been removed.

⚠️ What this article will not do is tell you what that difference means for outcomes. That is a clinical question, it is contested in the literature, and a distributor is not the party to settle it. What can be said with confidence is narrower and still useful: it is a compositional claim about the contents of the vial, it is the kind of claim a manufacturer can substantiate with process documentation, and it is absent from the ingredient line of the other nine brands in our range. Absent from the line is not the same as absent from the product, which is precisely the gap this piece is about.

It is also worth noticing where that claim appears and where it does not. CORETOX makes it on the ingredient line, which is the field a buyer reads first, and it makes it again in the licensed name on the register, where 코어톡스주 carries the 150kDa rendering. The Dysport licence records the opposite fact, the presence of a haemagglutinin complex, in its official product name. Between those two the information is public in both directions and in both places. For the remaining brands in our range neither statement appears in either field, which means the question is open rather than answered, and open questions are answered by manufacturer documentation rather than by inference from silence.

The same reading applies to INNOTOX and its ready to use liquid description. That is a form factor statement rather than a composition one, and form factor is one of the few properties this category does declare consistently. How liquid, vacuum dried and freeze dried presentations differ across Korean toxins is mapped in Korea's botulinum toxins, compared by maker, form and approval.

Where the differences actually live

If the ingredient line does not separate these products, something else must, because 21 licence holders did not build ten brands around an identical proposition. The distinguishing properties exist; they simply sit outside the field a buyer instinctively reads first.

The licence holder is the most consequential of them. Twenty-one companies hold the 58 licences, and the holder determines the manufacturing process, the quality system, the documentation you receive and who you are actually buying from. Our own product pages carry this where it is known: CORETOX is Medytox, LIZTOX is Huons Biopharma, Kamomis is Hugel. A brand name and a manufacturer are different facts, and only one of them appears in a register.

Presentation is the second. Whether a product arrives as a liquid or as a powder requiring preparation is a real operational difference for a clinic and a real logistics difference for a distributor, and it is declared reliably. Unit size is the third, and here the register is unusually explicit: licensed names routinely embed the strength, as in 메디톡신주 200단위 or 보툴렉스주50단위. That the number is in the licensed name rather than only on the carton is a small piece of verification value, because a name and a strength that disagree are a discrepancy you can see without opening anything.

Strength appearing in the licensed name is worth one more sentence because it is a rare piece of free verification. In most of the categories we handle, the quantity lives on the carton and in the specification sheet while the licensed name stays generic, which means a mismatch between the two is invisible without opening a document. Here the number is in the official record itself. That does not tell you anything about the product's quality, and it is not a substitute for provenance checks, but it is one comparison that costs nothing to run.

Export naming is the fourth, and in this category it is unusually dense. A single licence can carry several export names: one Medytox licence records Neuronox, Siax, Evosyal and Irocsin as export names for the same product. So two boxes with different brand names on them can be the same licensed product, which is the opposite of the problem this article opened with and just as capable of misleading a comparison table. What that marking does and does not imply is set out in what the export wording on a Korean licence means.

Twenty-one holders behind the names in circulation

Fifty-eight licences are held by 21 companies, which is a ratio of roughly three licences per holder and a much more concentrated field than the number of brand names on the market suggests.

Our own range shows how that concentration surfaces. Where the manufacturer is stated on our product pages it names companies rather than brands: CORETOX carries Medytox, LIZTOX carries Huons Biopharma, Kamomis carries Hugel. Those are three separate corporate entities behind three of the ten names we carry, and the remaining seven brands are distributed across the same small population of holders in a pattern the register can tell you and a carton cannot.

This matters more here than in categories with heterogeneous ingredient lines, precisely because the ingredient line has been ruled out as a discriminator. When composition is declared identically, the licence holder becomes the primary fact that distinguishes what you are buying, since it determines the manufacturing process, the quality system and the documentation chain behind the vial. A supplier who can name the holder is describing the product; one who can only name the brand is describing the label.

There is a second consequence that catches out anyone building a supplier comparison. Because one holder can carry several licences and one licence can carry several export names, the count of brand names in a quotation says almost nothing about how many distinct manufacturing sources are involved. Two quotes listing five brands each might represent five sources or two. The register resolves that; the brand list does not.

What to ask when the spec sheet is flat

The practical consequence is that a toxin comparison built from ingredient lines produces no information, and a buyer who stops there has not begun. Four questions restore the discrimination the spec sheet does not provide.

Ask who holds the licence, not who owns the brand, since 21 holders sit behind the names in circulation and the holder is the party whose process and documentation you are relying on. Ask what the presentation is, because liquid and lyophilised products differ in handling and in what arrives. Ask whether the licensed product name matches the strength and the brand on the carton, since Korean licensed names usually embed the unit count and any mismatch is visible. And ask whether the name you were quoted is a domestic product name or an export name, because one licence can carry four of the latter.

One thing not to ask is which brand is better, because that question cannot be answered from any of the records this article draws on, and a supplier who answers it confidently is answering from somewhere other than the documentation. The registers record what is licensed, by whom, in what form and under what classification. They do not rank, and neither do we. Treating a flat ingredient line as an invitation to seek a ranking elsewhere is how a sourcing conversation drifts into claims nobody can substantiate.

None of those questions is adversarial and all four are answerable from public records plus a supplier's own paperwork. They are also the questions that a flat ingredient line makes necessary rather than optional. In a category where composition is declared identically across ten brands, the verification burden shifts entirely onto provenance, and provenance is a documentation question rather than a specification one.

Across the KSTATION range these products sit in the botulinum toxins collection, and all of them are prescription only in Korea. Brand specific readings of the three largest lines are available separately for INNOTOX, NABOTA and BOTULAX, and the authenticity checks that apply across all of them are collected in how to verify an authentic Korean botulinum toxin.

Disclaimer. This article is general educational information and is not medical advice. It describes how the declared active is recorded on product pages and in the Korean drug register across botulinum toxin brands, and which properties are and are not carried by an ingredient line. It does not compare products on effect, quality, suitability or interchangeability, and it gives no guidance on units, dilution, preparation, storage, handling or administration. Botulinum toxin products are prescription-only in Korea and are supplied for professional use by licensed practitioners. Regulatory status varies by country and changes over time.